The Hidden Cost of Health: Why Australians Pay More for Medical Devices
There’s a quiet scandal brewing in Australia’s healthcare system, and it’s one that most people haven’t even heard of. Buried in a 10,000-item list of medical devices is a story of inflated prices, corporate profits, and a political system that seems unwilling—or perhaps unable—to fix it. What makes this particularly fascinating is how a single agreement, made in the shadows of a federal election, has locked millions of Australians into paying some of the highest prices in the world for surgical hardware.
The Deal That Changed Everything
In the weeks leading up to the 2022 federal election, then-health minister Greg Hunt struck a deal that would reshape Australia’s medical device market. On the surface, it seemed like a routine agreement—a way to manage costs and ensure access to cutting-edge technology. But what many people don’t realize is that this deal went against the advice of federal bureaucrats, who warned it would disproportionately benefit the medical device industry at the expense of Australian consumers.
Personally, I think this is where the story gets interesting. Instead of dismantling the agreement, the incoming Labor government not only endorsed it but also instructed their department to enforce its terms. Why? Because, as Hunt argues, the deal was supposed to put downward pressure on insurance premiums. But here’s the kicker: it didn’t. Premiums remained high, and Australians continued to pay up to three times more for surgical hardware than patients in other countries.
The Prescribed List: A Hidden Price Tag
At the heart of this issue is the Prescribed List, a little-known schedule that dictates what private health funds must pay hospitals for over 10,000 medical devices. From pacemakers to surgical staples, these prices are often far higher than what public hospitals pay for the exact same products. One thing that immediately stands out is the sheer scale of the price gap. For example, in 2023, private insurers paid $36,500 for the most popular implanted cardiac defibrillator, while public hospitals paid just $14,500 for the same device.
If you take a step back and think about it, this system effectively isolates medical device manufacturers from normal commercial competition. As health economist Stephen Duckett points out, it’s a legalized transfer of wealth from Australians paying private health insurance premiums straight to multinational device companies. What this really suggests is that the system is rigged—and neither major political party has shown the will to fix it.
The Broader Implications
What makes this issue so troubling is its broader implications. It’s not just about the cost of medical devices; it’s about the erosion of trust in a healthcare system that’s supposed to prioritize patients over profits. From my perspective, this raises a deeper question: Why are we allowing a system to persist that forces consumers to subsidize corporate profits?
A detail that I find especially interesting is the role of private health insurers. The medical device industry argues that insurers pocket the savings when device prices drop instead of passing them on to policyholders. Whether or not this is true, it highlights a systemic lack of transparency and accountability. Meanwhile, statistics show that private health insurers generated $2.1 billion in net profit last year, while management expenses climbed to $3.4 billion.
The Way Forward
So, where do we go from here? A recent review by the Nous Group recommended that the Australian government urgently review the role of international benchmarking in setting device prices. This is a step in the right direction, but it’s only the beginning. In my opinion, what’s needed is a complete overhaul of the system—one that prioritizes fairness, transparency, and affordability for Australian consumers.
What many people don’t realize is that this isn’t just a financial issue; it’s a moral one. When patients are forced to pay exorbitant prices for life-saving devices, it undermines the very principle of healthcare as a public good. If we’re serious about fixing this, we need political leaders who are willing to stand up to industry lobbyists and put the interests of Australians first.
Final Thoughts
As I reflect on this issue, I’m struck by how easily it’s been swept under the rug. The Prescribed List isn’t just a list of medical devices—it’s a symbol of a system that’s broken. But it’s also an opportunity. By shining a light on this hidden cost, we can start a conversation about what kind of healthcare system we want. Personally, I think it’s time for a change. Not just for the sake of affordability, but for the sake of fairness and equity. After all, healthcare isn’t a luxury—it’s a right. And it’s time we started treating it like one.
